论文部分内容阅读
钾通道开放剂 ( KCO)作用多样 ,可以保护心脏和其他组织 ,对抗缺血坏死 ,在心肌梗死和中风中有益。新的研究表明 ,不同于经典的细胞膜表面 ATP依赖性钾通道 ( KATP) ,线粒体 KATP可能是 KCO心脏保护作用的效应器。本文主要综述线粒体通道及以此为靶点开发新药的展望。
Potassium channel openers (KCOs) have a diverse range of actions that protect the heart and other tissues against ischemia and necrosis and are beneficial in myocardial infarction and stroke. New research shows that, unlike the classical plasma membrane-bound ATP-dependent potassium channel (KATP), mitochondrial KATP may be an effector of KCO cardioprotection. This article reviews the mitochondrial pathway and prospects for the development of new drugs.